Canadian Manufacturing

Automotive manufacturer Plasman expands in the southern U.S.

The production facility, built in 2016, is an exterior trim paint plant that has capability for full fascia/bumper.

October 13, 2021  by CM Staff

Minghau USA, Inc. – South Carolina (CNW Group/Plasman)

WINDSOR — Automotive and manufacturing company Plasman announces their recent acquisition of Minghua USA, a tier-one automotive manufacturing and sequencing company located in Greer, South Carolina. Minghua was introduced to Plasman by their current customer BMW. The production facility, built in 2016, is an exterior trim paint plant that has capability for full fascia/bumper.

This is the fourth acquisition by Plasman since 2015, and expands global operations to 17 manufacturing sites worldwide. “Adding the Greer manufacturing site to our portfolio grows Plasman’s planned footprint and allows us to expand our current European customer relationships with BMW and Volvo here in North America. Additionally, through the acquisition Plasman adds Volkswagen as a new customer with upcoming product launches in 2022 and 2023,” noted Plasman President & CEO David Wiskel.

The new site, located at the Velocity Industrial Park in Greer, is a mold, paint, bonding and assembly plant location with JIT assembly and sequencing capabilities. It is equipped with 16 injection mold machines with tonnage up to 4000t and a Sturm-Eisenmann fascia paint system that can provide capacity to manufacture 1,000,000 bumpers per year.

“Strategically the site rounds out our southern USA footprint and supports some of the most advanced automotive products on the market, including full exterior for the upcoming launch of the new BMW G09 and a complex exterior package for the Volvo XC90 Electric Vehicle,” stated Plasman President, North America Tim Berezowski.

Advertisement

Plasman is a supplier of exterior trim, bumpers/fascia, and sub-components for major OEM automotive brands, and is a player in the consumer goods market specializing in precision molding. Recently, the Company also further diversified into the medical device and biotech industry.